Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) Market Outlook

Thelansis’s “Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Allogeneic Hematopoietic Stem Cell Transplantation treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) Overview

Hematopoietic stem cell transplant (HSCT) is a procedure where healthy hematopoietic stem cells are given to patients with dysfunctional or depleted bone marrow. HSCT therapy is used for both malignant (Acute myeloid leukemia, Myelodysplastic syndromes, Chronic myeloid leukemia, Acute lymphoblastic leukemia, Myeloproliferative disorders, Non-Hodgkin’s lymphoma, Multiple myeloma, Chronic lymphocytic leukemia, Hodgkin’s disease, Juvenile chronic myeloid leukemia)and non-malignant (Aplastic anemia, Paroxysmal nocturnal hemoglobinuria, Fanconi’s anemia, Blackfan-Diamond anemia, Thalassemia major, Sickle cell anemia, Severe combined immunodeficiency, Wiskott-Aldrich syndrome and Inborn errors of metabolism) diseases. In allogeneic hematopoietic stem cell transplantation (HSCT), the stem cells are sourced from a donor different from the recipient. Typically, the donor and recipient share a degree of genetic compatibility known as HLA (human leukocyte antigen) matching, determined by the genes found on chromosome 6. Each individual inherits a set of MHC (major histocompatibility complex) alleles, forming HLA pairs. Crucial HLA loci include HLA-A, HLA-B, HLA-C, HLA-DR, and HLA-DQ. The selection of a donor for allogeneic HSCT considers several factors, including the patient's specific disease, disease stage, and the urgency of finding a suitable donor. In cases where allogeneic HSCT is being contemplated, having a fully HLA-matched sibling as the donor is the preferred choice. This preference is due to the lower risk of graft rejection and graft-versus-host disease (GvHD) when using allogeneic stem cells from a fully HLA-matched sibling. Stem cells can be obtained from three sources:

1. Bone Marrow: This involves a surgical procedure using hollow needles to extract liquid bone marrow from the hip bones. Anticoagulants are added to prevent clumping, and sterile filters remove impurities. Bone marrow can be stored at room temperature, in a refrigerator for a limited time, or cryopreserved for longer storage.
2. Peripheral Blood Progenitor Cells (PBPCs): PBPCs containing HPCs are collected from peripheral blood using an apheresis device. A growth factor is usually administered before collection. Autologous PBPC donors may receive chemotherapy. PBPCs can be stored at room temperature, in refrigerators, or cryopreserved like bone marrow.
3. Umbilical Cord Blood (UCB): UCB, once considered waste, is collected safely after childbirth. Further processing removes red blood cells, which are cryopreserved for future use. UCB can be stored privately or publicly for unrelated recipients.

Complications following a bone marrow transplant can be acute or chronic and are influenced by various factors, including age, performance status, stem cell source, and preparative regimen. Acute complications occur within the first 90 days, including myelosuppression, sinusoidal obstruction syndrome, mucositis, graft-versus-host disease, bacterial and viral infections, and fungal infections. Chronic complications encompass chronic GVHD, infections with encapsulated bacteria, and varicella-zoster virus reactivation. The number of allogeneic HCTs performed in the USA increased compared to autologous HCTs. The most common type of allogeneic HCT was from an unrelated donor, followed by transplants from a related donor.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: